What is the primary driver behind the decline in gross profit despite revenue growth?

The decline in gross profit is primarily attributed to the transition of the Pharmaceutical Distribution segment's business model from one reliant on manufacturer price increases and buy-side opportunities to a fee-for-service model. This transition, coupled with specific events like product recalls from a generic supplier and charges related to discontinuing automation products, negatively impacted gross profit margins.

How has the company's cash flow situation changed?

The company's cash flow from operations has significantly improved, showing a substantial increase for the nine months ended June 30, 2005. This improvement is largely due to aggressive inventory reduction efforts, as part of the business model transition, and effective management of accounts payable.

What is the impact of the Medicare Modernization Act on Cencora's business?

The full impact of the Medicare Modernization Act on the company's PharMerica segment (Long-Term Care business) cannot be determined at this time. While the company is evaluating the effects, the new regulations, particularly the voluntary prescription drug benefit program, could potentially have an adverse effect on its Long-Term Care business due to changes in reimbursement and healthcare provider dynamics.

What is the significance of the change in accounting for cash discounts and manufacturer incentives?

The change in accounting for cash discounts and manufacturer incentives, effective October 1, 2004, was made to better align with the company's transition to a fee-for-service model. This change, which resulted in a $10.2 million cumulative effect charge, is intended to provide a more objective method of recognizing discounts and a better matching of inventory costs to revenue as inventory turnover rates are expected to improve.

COR 10-Q Quarterly Report Q3 FY2005 — Revenue, Net Income, EPS

Summary

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported its quarterly results for the period ending June 30, 2005. The company saw an increase in operating revenue, primarily driven by its Pharmaceutical Distribution segment. However, gross profit and operating income experienced a decline compared to the previous year, largely due to a shift in the business model towards a fee-for-service approach, product recalls from a generic supplier, and the discontinuation of certain automation product offerings. Despite the decline in profitability, the company demonstrated strong cash flow generation, significantly improving its cash flow from operations due to a reduction in merchandise inventories and effective working capital management. Cencora also continued its share repurchase program, demonstrating a commitment to returning capital to shareholders. The company is navigating regulatory changes, particularly related to the Medicare Modernization Act, with uncertain future impacts on its PharMerica segment.

Key Highlights

1Operating revenue increased by 4% to $12.6 billion for the quarter, driven by the Pharmaceutical Distribution segment.
2Gross profit decreased by 12% to $502.1 million, impacted by a business model transition, product recalls, and a charge for discontinuing automation product offerings.
3Operating income declined by 33% to $168.6 million, reflecting lower gross profit and specific charges.
4Cash flow from operations significantly improved, reaching $1.25 billion for the nine months ended June 30, 2005, largely due to inventory reductions and increased accounts payable.
5The company repurchased $94.2 million of common stock during the quarter under a $450 million authorization, and has completed previous repurchase programs.
6The company changed its method of recognizing cash discounts and manufacturer incentives to align with a fee-for-service model, recording a $10.2 million charge for the cumulative effect.
7Interest expense decreased by 58% year-over-year due to reduced average borrowings.

Cencora, Inc. Quarterly Report for Q3 Ended Jun 30, 2005

Summary

Key Highlights

Frequently Asked Questions